Inflammation and atherogenic markers in patients with type 2 diabetes mellitus.

Autor:	Maravilla Domínguez MA; Facultad de Ciencias de la Salud, Universidad Juárez del Estado de Durango, Gómez Palacio, Durango, México., Zermeño González ML; Unidad Médica Especializada en Enfermedades Crónicas, Lerdo, Durango, México; Hospital General de Zona # 46, Instituto Mexicano del Seguro Social, Gómez Palacio, Durango, México., Zavaleta Muñiz ER; Unidad Médica de Alta Especialidad, Instituto Mexicano del Seguro Social, Torreón, Coahuila, México., Montes Varela VA; Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Gómez Palacio, Durango, México., Irecta Nájera CA; El Colegio de la Frontera Sur, Unidad Villahermosa Tabasco, Departamento de Salud, Villa Hermosa, Tabasco, México., Fajardo Robledo NS; Laboratorio de Investigación y Desarrollo Farmacéutico, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Jalisco, México., Zavaleta Muñiz SA; Facultad de Ciencias de la Salud, Universidad Juárez del Estado de Durango, Gómez Palacio, Durango, México. Electronic address: zams2109@yahoo.com.mx.
Jazyk:	English; Spanish; Castilian
Zdroj:	Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis [Clin Investig Arterioscler] 2022 May-Jun; Vol. 34 (3), pp. 105-112. Date of Electronic Publication: 2021 Jun 03.
DOI:	10.1016/j.arteri.2021.03.006
Abstrakt:	Type two diabetes mellitus (T2DM) is characterized by a chronic inflammation status. Altered markers such as lipid concentrations are usually found in this disease. Elevated inflammation markers have been described such as cytokines (interleukin 6, tumour necrosis factor-alpha, and IL-8). However, there is a lack of information about the behaviour of the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), lipid coefficients, and atherogenic index in T2DM. Objective: To describe the atherogenic and inflammation parameters in a group of patients with T2DM. Materials and Methods: 42 patients with T2DM were included, all patients were surveyed on clinic history (disease history, comorbidity, smoking, and other relevant variables), measurements of haematological, biochemical, and anthropometric parameters were taken and atherogenic coefficients and inflammation ratios were calculated. Results: Inflammation markers such as interleukin 6 and 8, necrosis tumour factor, and NLR were elevated. Of the patients, 88% were classified as high risk according to the atherogenic index. Former smokers had lower levels of IL-8 and higher NLR than non-smokers. Conclusion: The atherogenic and inflammation markers such as atherogenic index, IL-8, and NLR make it possible to identify a subgroup of patients that are at risk of severe complications and mortality. (Copyright © 2021 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu